StimuSIL Unveils New Review on Non-Drug Treatments for Hair Loss
Delaware, US; August 2nd, 2024
StimuSIL is excited to announce the publication of a new narrative review, “Physical Treatments and Therapies for Androgenetic Alopecia“, in the Journal of Clinical Medicine. This review explores the latest advancements in non-drug treatments for androgenetic alopecia, the most common form of hair loss affecting millions of men and women worldwide. The article also emphasizes the benefits of physical therapies, which are just as effective as drug-based treatments but have fewer side effects. Use of physical treatments can improve hair growth, stop hair loss, and improve patient happiness, especially when combined approaches are offered.
Key Takeaways
Authored by StimuSIL’s VP of Clinical Research Dr. Siddhi Camila Lama and CSO Dr. Mehmet Kosoglu, along with experts Dr. Robert Dennis, Dr. Daniel Ortega-Quijano, and Dr. Luis Alfonso Pérez-González, this review covers various non-drug treatment options for hair loss. It focuses on therapies like low-level laser therapy (LLLT), microneedling, and pulsed electromagnetic field (PEMF) therapy, highlighting their benefits and how they work.
The combination of laser hair therapy and microneedling are notably at the core of StimuSIL’s SAGA-001 device, while PEMF is the key technology behind its new StimuField wearable. Both aim to enhance hair and scalp health.
Just like medications, physical therapies can be more effective when used together. But unlike most drugs, physical therapies have fewer side effects, making them safer to combine. Using physical treatments together can also produce the need for fewer treatment sessions, which is more convenient for patients. The review explores how combining treatments like LLLT and PEMF, or LLLT and microneedling, can offer better results. StimuSIL’s SAGA-001 is designed with this multimodal approach in mind.
The review also highlights future research directions, calling for more clinical trials to validate, optimize, and improve these treatments.
StimuSIL is committed to developing innovative medical devices to treat hair loss and other conditions. They are concluding their first clinical trial using SAGA-001 for male androgenetic alopecia and have recently licensed technology to explore PEMF for hair growth. StimuSIL continues to support research and innovation in dermatology and aesthetics.
Click on the buttons below to download or read the open access article on the MDPI website.